Juan-Pablo Mas is a Partner at Action Potential VC, a bioelectronic medicine fund founded by GlaxoSmithKline, and is based in Santa Cruz, CA. He represents APVC on the Boards of Cala Health, Exo Imaging, Neuspera Medical, Presidio Medical, Saluda Medical, SetPoint Medical, and previously CVRx. Prior to APVC, he was an investor at Lightstone Ventures and Morgenthaler Ventures, where he was a Board observer at Ardian, Twelve, Nuvaira, Cabochon, and Miramar Labs. Prior to investing, Juan-Pablo led R&D and Strategy teams in Medtronic’s CardioVascular Division and was a member of the Global Brand Strategy team at Eli Lilly. Juan-Pablo earned an MBA from the Stanford Graduate School of Business as a Bonini Fellow, an MS in Electrical Engineering from Stanford University, and a BS in EE from the University of Massachusetts. He now serves on the Oversight Committee for Stanford’s Wu Tsai Neuroscience Institute, the Advisory Board for UCSF’s Rosenman Institute, the DEI Advisory Committee for RockHealth.org, and is a co-founder of the non-profit LatinxVC which is dedicated to increasing diversity within venture capital. Juan-Pablo is originally from Puerto Rico and played Division I men’s lacrosse at UMass.